memo - Magazine of European Medical Oncology

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Practice changing data and new developments in the management of prostate cancer – ASCO 2010
memo - Magazine of European Medical Oncology - Tập 3 - Trang 164-166 - 2012
M. De Santis, M. Bachner
In the 2010 ASCO meeting valuable information and even practice-changing results for the medical treatment of castration resistant prostate cancer (CRPC) were presented. Focus was put on bone-targeted treatment, chemotherapy for second line use, combinations of standard chemotherapy with different new drugs and data on a novel antiangiogenic compounds. Denosumab was shown to be superior to zoledro...... hiện toàn bộ
Therapy with JAK 1/2 inhibitors for myelofibrosis
memo - Magazine of European Medical Oncology - Tập 6 - Trang 109-113 - 2013
Franz Romeder, Richard Greil, Alexander Egle
Myelofibrosis (MF) is currently the myeloproliferative disorder with the most severe prognosis. A mutation of the JAK2 (V617F) enzyme is present in about 65 % of patients. Inhibition of JAK-kinases was therefore a proposed treatment for the disease. The purpose of this article is to give an updated overview about the recent developments in the therapy of MF with JAK-inhibitors. We did a research t...... hiện toàn bộ
Gastrointestinal cancers – still many questions to be resolved
memo - Magazine of European Medical Oncology - Tập 4 - Trang 61-61 - 2011
E. Wöll
A GLOBAL CONGRESS DIGEST ON ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 7th – 9th December 2022
memo - Magazine of European Medical Oncology - Tập 16 - Trang 53-64 - 2023
Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria
memo - Magazine of European Medical Oncology - Tập 5 - Trang 289-295 - 2012
Claudia Zimmermann, Ulrike Pötschger, Gabriele Amann, Ernst Horcher, Karin Dieckmann, Karoly Lakatos, Christian Urban, Herwig Lackner, Michael Höllwarth, Bernhard Meister, Roman Crazzolara, Georg Ebetsberger, Franz Martin Fink, Neil Jones, Agnes Gamper, Reinhard Moser, Reinhold Kerbl, Barbara Jauk, Walter Pobegen, Martin Henkel, Bernd Ausserer, Waltraud Friesenbichler, Judith Böhm, Norbert Graf, Wolfgang Holter, Helmut Gadner, Andreas Zoubek, Leo Kager
The overall outcome for children with nephroblastomas is excellent when treated according to protocols that include surgery, chemotherapy, and, in selected cases, radiotherapy. This study was conducted to provide population-based data on Austrian children who had been treated in neoadjuvant nephroblastoma trials between October 1988 and July 2001. One hundred and forty-eight children with newly di...... hiện toàn bộ
Highlights in surgery of brain tumours
memo - Magazine of European Medical Oncology - Tập 3 - Trang 6-8 - 2010
V. V. Dolenc, I. J. Kocijančič, R. Pregelj
The largest possible and safe removal of the lesion (also malignant) is the best first step of treatment. The extra-axial benign lesions do require the best possible surgical treatment, ideally a complete resection of the lesion without endangering the surrounding neural and/or vascular structures. The most frequent extra-axial intracranial tumours are: pituitary tumours, craniopharyngiomas, centr...... hiện toàn bộ
The individualization of treatment based on molecular markers
memo - Magazine of European Medical Oncology - Tập 5 - Trang 251-252 - 2012
Vladimir M. Moiseyenko
Recent developments have revealed various decisive discoveries in individualized oncology for many different entities—the individualization of treatment based on molecular markers representing just one of those milestones. The implication of epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitor (TKI) treatment, the definition of the HER2 status in breast cancer and t...... hiện toàn bộ
Immunotherapy in hepatocellular carcinoma
memo - Magazine of European Medical Oncology - Tập 13 - Trang 218-222 - 2020
Stephanie Hametner-Schreil
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers. The prognosis remains poor—the 5‑year overall-survival (OS) is 12–18%, all stages taken together. Systemic therapy has been limited to the use of tyrosine kinase inhibitors for more than a decade. Now immune therapy has also arrived in the field of systemic HCC treatment. Despite initial enthusiasm, the respons...... hiện toàn bộ
Cancer of unknown primary—state of the art
memo - Magazine of European Medical Oncology - - 2024
Thorsten Fuereder
SummaryThe Cancer of Unknown Primary (CUP) syndrome does not represent a single clinical entity but comprises a diverse group of malignant tumors. CUP is defined as a histologically confirmed metastatic malignant disease for which the primary tumor cannot be identified after completing initial diagnostics. Although its incidence has decreased, managing CUP patients...... hiện toàn bộ
Open Access publizieren in „memo – magazine of european medical oncology“
memo - Magazine of European Medical Oncology - Tập 9 - Trang 1-1 - 2016
Alois Sillaber
Tổng số: 854   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10